320 related articles for article (PubMed ID: 16873561)
1. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.
Zhu CQ; Shih W; Ling CH; Tsao MS
J Clin Pathol; 2006 Aug; 59(8):790-800. PubMed ID: 16873561
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers.
Au NH; Cheang M; Huntsman DG; Yorida E; Coldman A; Elliott WM; Bebb G; Flint J; English J; Gilks CB; Grimes HL
J Pathol; 2004 Sep; 204(1):101-9. PubMed ID: 15307143
[TBL] [Abstract][Full Text] [Related]
4. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
Singhal S; Vachani A; Antin-Ozerkis D; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Jun; 11(11):3974-86. PubMed ID: 15930332
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
7. High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC).
Sonnweber B; Dlaska M; Skvortsov S; Dirnhofer S; Schmid T; Hilbe W
J Clin Pathol; 2006 Mar; 59(3):255-9. PubMed ID: 16505275
[TBL] [Abstract][Full Text] [Related]
8. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
Yaren A; Oztop I; Kargi A; Ulukus C; Onen A; Sanli A; Binicier O; Yilmaz U; Alakavuklar M
Int J Clin Pract; 2006 Jun; 60(6):675-82. PubMed ID: 16805752
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
10. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
[TBL] [Abstract][Full Text] [Related]
11. Role of p53 and EGFR as prognostic biomarkers in stage I non-small cell lung cancer.
Donahue JM
J Surg Oncol; 2014 Aug; 110(2):97-8. PubMed ID: 24895315
[No Abstract] [Full Text] [Related]
12. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
Brambilla E; Moro D; Gazzeri S; Brambilla C
J Pathol; 1999 Aug; 188(4):351-60. PubMed ID: 10440744
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer.
Berghmans T; Meert AP; Martin B; Ninane V; Sculier JP
Eur Respir J; 2005 Feb; 25(2):329-35. PubMed ID: 15684299
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma.
Shepherd FA; Tsao MS
J Clin Oncol; 2010 Feb; 28(6):903-5. PubMed ID: 20100955
[No Abstract] [Full Text] [Related]
15. Predicting non-small cell lung cancer expression of epidermal growth factor receptor and matrix metalloproteinase 9 from immunohistochemical staining of diagnostic biopsy samples.
Ferrigan L; Wallace WA
Eur J Cancer; 2004 Jul; 40(10):1589-92. PubMed ID: 15196544
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer.
Cooper WA; Kohonen-Corish MR; McCaughan B; Kennedy C; Sutherland RL; Lee CS
Histopathology; 2009 Jul; 55(1):28-36. PubMed ID: 19614764
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53.
Hirabayashi H; Ohta M; Tanaka H; Sakaguchi M; Fujii Y; Miyoshi S; Matsuda H
J Surg Oncol; 2002 Dec; 81(4):177-84; discussion 184. PubMed ID: 12451621
[TBL] [Abstract][Full Text] [Related]
18. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma.
Dalquen P; Sauter G; Torhorst J; Schultheiss E; Jordan P; Lehmann S; Solèr M; Stulz P; Mihatsch MJ; Gudat F
J Pathol; 1996 Jan; 178(1):53-8. PubMed ID: 8778317
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.
Hommura F; Dosaka-Akita H; Mishina T; Nishi M; Kojima T; Hiroumi H; Ogura S; Shimizu M; Katoh H; Kawakami Y
Clin Cancer Res; 2000 Oct; 6(10):4073-81. PubMed ID: 11051259
[TBL] [Abstract][Full Text] [Related]
20. Prognostic evaluation of CapG, gelsolin, P-gp, GSTP1, and Topo-II proteins in non-small cell lung cancer.
Zhu WY; Hunag YY; Liu XG; He JY; Chen DD; Zeng F; Zhou JH; Zhang YK
Anat Rec (Hoboken); 2012 Feb; 295(2):208-14. PubMed ID: 22190510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]